Lipoprotein(a) — said "L-P-little-a" — is a cholesterol particle whose blood level is roughly 70-90% set by the genes you inherited, and which barely budges with diet or exercise. It raises the risk of heart attack, stroke, and aortic valve stenosis independently of LDL, so a reassuring standard cholesterol panel does not rule it out. Because levels are stable across adult life, major guidelines now say to measure it at least once — one blood draw, once, forever. Around one in five people are elevated, and almost none of them know.
Why isn't Lp(a) on a normal cholesterol panel?
A standard lipid panel reports total cholesterol, LDL, HDL, and triglycerides. Lp(a) is a separate order. It has historically been left off for practical reasons: for decades there was nothing to do about a high result, assays disagreed with each other, and no US guideline required it. All three of those things are changing.
Structurally, Lp(a) is an LDL particle with an extra protein — apolipoprotein(a) — wrapped around it. That add-on makes the particle both atherogenic (it drives plaque like LDL does) and pro-inflammatory, and it resembles a clotting protein closely enough that researchers have long suspected a thrombotic contribution too. It also deposits in the aortic valve, which is why Lp(a) is one of the few blood markers genetically linked to calcific aortic stenosis — a valve problem, not a plumbing problem.
The evidence that this is causal rather than merely correlated comes from Mendelian randomization: people who inherit LPA gene variants that raise Lp(a) from birth have more cardiovascular disease, in a dose-dependent way, across ethnic groups. That is a much stronger form of evidence than an observational association, and it is why the European Atherosclerosis Society's 2022 consensus statement describes the relationship as causal and continuous.
What counts as high, and how reliable is the number?
Two units are in circulation, and they are not interchangeable — mg/dL measures mass, nmol/L counts particles, and because apo(a) size varies enormously between people, no conversion factor is truly accurate. Ask which unit your lab used, and compare like with like.
| Result | What it means | What it typically changes |
|---|---|---|
| Below 30 mg/dL (<75 nmol/L) | Widely used as a low-risk range; Lp(a) is unlikely to be adding meaningfully to your risk | Nothing specific. Risk is assessed on the usual factors. No repeat test needed. |
| 30-50 mg/dL (75-125 nmol/L) | Grey zone — genuinely uncertain, not a red flag | Interpreted alongside family history and other risk factors; may tip a borderline decision |
| 50 mg/dL or above (≥125 nmol/L) | Elevated. This is the level the European Atherosclerosis Society treats as a risk enhancer; population studies put the associated long-term excess risk of heart attack or stroke at roughly 1.3-1.5-fold | More intensive attention to LDL, blood pressure, smoking, and diabetes; testing for first-degree relatives |
| Around 100 mg/dL (roughly 250 nmol/L) or above | Markedly elevated; the EAS estimates that about 100 mg/dL approximately doubles ASCVD risk, whatever your baseline risk | Same levers, applied harder; some clinicians add coronary artery calcium imaging to clarify |
Two honest caveats. First, these cutoffs are pragmatic lines drawn across a continuous risk curve — 49 and 51 mg/dL are not different diseases. Second, assays and reference ranges still vary between laboratories, so a value near a cutoff deserves interpretation by a clinician who knows your full picture rather than a verdict from the number alone. Our lab results explainer can help you read the report before that conversation.
Why Lp(a) matters differently for women in midlife
Estrogen suppresses expression of the LPA gene — the mechanism is well described, down to apo(a) mRNA regulation in animal models. When estrogen falls across the menopause transition, that brake comes off and Lp(a) tends to rise.
The size of that effect deserves to be stated carefully rather than inflated. A 2023 systematic review and meta-analysis in Maturitas, pooling roughly 4,700 premenopausal and 8,300 postmenopausal women, found postmenopausal levels about 3.8 mg/dL higher. But in the four studies that matched women for age, and in the studies measuring women before and after bilateral oophorectomy, that difference disappeared — so the authors concluded that transition to menopause may raise Lp(a), while the contribution of ageing cannot be separated out with current data. What is more consistently documented is where women end up: postmenopausal women run around 17% higher than men.
Individually those shifts are modest. Collectively they matter, because they land on a group whose cardiovascular risk is already systematically underestimated. Risk calculators built largely on male cohorts miss female-specific contributors — a history of preeclampsia, gestational diabetes, premature ovarian insufficiency, autoimmune disease. Women's heart attack symptoms are recognised later. A one-time Lp(a) result is one of the few pieces of hard, personal, permanent data that can pull a midlife woman's risk assessment closer to the truth. See also our guides to menopause and heart health and women's heart health.
One thing this does not mean: an elevated Lp(a) is not a reason to start or avoid hormone therapy. Hormone therapy does lower Lp(a) — meta-analyses put the reduction around 20-25% — but lowering it that way has never been shown to reduce cardiovascular events, and expert statements are explicit that this is not a reason to use it. Hormone therapy decisions are made on symptoms, timing, and personal risk, with your clinician, not on the basis of this one number.
Who should be tested?
The 2026 ACC/AHA/Multisociety dyslipidemia guideline, published in March 2026, recommends Lp(a) be measured at least once in adulthood — the first time a US guideline has advised this broadly. Its stated rationale is exactly the one above: levels are largely genetically determined and remain relatively stable over a lifetime, so repeat testing is generally unnecessary. The European Atherosclerosis Society reached the same conclusion in 2022, and the National Lipid Association endorses opportunistic or universal screening.
The case is strongest if you have a personal history of heart attack or stroke, a family history of early cardiovascular disease (before roughly 55 in men, 65 in women), familial hypercholesterolemia, cardiovascular disease despite well-controlled LDL, recurrent events on treatment, calcific aortic stenosis, or a first-degree relative with known high Lp(a). South Asian and Black populations tend to have higher average levels, though risk is elevated across all ancestries.
You do not need to fast, and there is no need to repeat the test in most cases. If you want to think through your broader risk picture first, our heart risk check walks through the standard factors.
What actually changes if your Lp(a) is high?
Here is the part most articles skip, and it is the honest core of this topic: there is currently no approved medication that lowers Lp(a) specifically and has been proven to reduce heart attacks or strokes.
Statins do not lower Lp(a) — by raising hepatic LDL-receptor activity they may nudge it slightly upward — though their overall benefit is unaffected and unrelated. PCSK9 inhibitors lower it by roughly 20-30% as a side effect, but that is not their indication. Niacin lowers it by roughly 20-30% and failed to improve outcomes in trials. Lipoprotein apheresis, a filtering procedure, is the only FDA-cleared route to lowering Lp(a) in the US and is reserved for rare, extreme cases. Diet and exercise do essentially nothing to the number — which is not a reason to skip either, since both act powerfully on everything else.
Several targeted therapies — pelacarsen, olpasiran, lepodisiran, zerlasiran, and the oral agent muvalaplin — reduce Lp(a) by 80-95% in trials. All of them are investigational and none is available by prescription. The first cardiovascular outcomes trial, Lp(a)HORIZON, has been running since 2019 in more than 8,000 people with established cardiovascular disease; its results were expected during 2026 and had not been published as of mid-2026. Until they are published and independently reviewed, no one can honestly say whether lowering Lp(a) lowers events. Be wary of clinics or supplements marketing Lp(a) lowering today.
So a high result changes management by making everything else more aggressive:
- LDL cholesterol. Guidelines treat elevated Lp(a) as a risk-enhancing factor arguing for a lower LDL target and earlier or more intensive lipid-lowering therapy. What that means for you is your prescriber's call — see statins in women and high cholesterol in women.
- Blood pressure. Tighter control matters more when your baseline arterial risk is higher.
- Smoking. The interaction between smoking and high Lp(a) is worse than either alone. This is the single highest-value change available.
- Better imaging of your actual arteries. A coronary calcium score or apoB can convert an abstract inherited risk into a concrete picture of what your arteries look like now.
- Family screening. Elevated Lp(a) is inherited in a roughly autosomal dominant pattern, so each first-degree relative — parents, siblings, adult children — has about a 50% chance of being elevated too. Published cascade-screening data bear that out: roughly one new case is found for every two first-degree relatives tested. It is one of the most efficient things a high result unlocks, and the reason to tell your family.
That is a real, meaningful set of actions. It is not nothing. But it is also not "treat the number," and anyone telling you otherwise in 2026 is ahead of the evidence.
When to see a doctor
Call 911 (or your local emergency number) immediately for chest pain or pressure, pain spreading to the jaw, neck, back, or arm, sudden shortness of breath, cold sweat with nausea, or unusual crushing fatigue with any of these. In women these symptoms are more often atypical and more often dismissed. For sudden face drooping, arm weakness, or speech difficulty, call emergency services — stroke treatment is time-critical.
Make a non-urgent appointment to discuss Lp(a) testing if you have a family history of early heart disease or stroke, a relative with known elevated Lp(a), cardiovascular disease despite good cholesterol numbers, aortic stenosis, familial hypercholesterolemia, or you are moving through menopause and have never had a full cardiovascular risk assessment. Bring the number, the units, and the lab's reference range. Explore more at heart health or find a clinician through find care.
This article is for information, not diagnosis. Lab values are reference ranges, not verdicts, and no medication should be started, stopped, or changed except by the clinician who prescribes it.
